Výsledky vyhledávání - "E. Magherini"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

Autor: F. Dubin, E. Magherini, Dorothée Semiond, C. Villanueva, Jean-Pascal Machiels, Mario Campone, Ahmad Awada, T. Besse, Xavier Pivot

Publikováno v: European Journal of Cancer. 47:1037-1045

BACKGROUND: Most patients with metastatic breast cancer (MBC) progress after chemotherapy. Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines. The objectives of this phase I/II study were to assess the ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d22b3a02a58ba629bb0946b16d9873f
https://doi.org/10.1016/j.ejca.2011.01.001

Zobrazit plný text záznamu

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

Autor: Dominique Méry-Mignard, Lucile Awad, David Cunningham, Emmanuel Mitry, E. Van Cutsem, Ph. Rougier, J.-Y. Douillard, E. Magherini

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 15(7)

Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinote

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e258af208fa956af0ca75c0f61815a0
https://pubmed.ncbi.nlm.nih.gov/15205193

Zobrazit plný text záznamu

Acute myelogenous leukemia with T-cell features

Autor: V, Ribrag, C, Bayle, P, Brault, S, Bodis, E, Magherini, M, Hayat

Publikováno v: Bulletin du cancer. 79(12)

From May 1985 to June 1990, 94 newly diagnosed cases of acute myelogenous leukemia (AML) were treated at the Institut Gustave-Roussy, of which four (4.3%) demonstrated mixed cell lineage. All these cases were morphologically and cytochemically consid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4e860ef914bb690c2d6713a53aa8f406
https://pubmed.ncbi.nlm.nih.gov/1304836

Zobrazit plný text záznamu

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results

Autor: Xavier Pivot, E. Magherini, Mario Campone, Dorothée Semiond, T. Besse-Hammer, Cristian Villanueva, F. Dubin, J-P. Machiels, Ahmad Awada

Publikováno v: Journal of Clinical Oncology. 27:1053-1053

1053 Background: Cabazitaxel (X), a new taxoid showed activity in taxane resistant MBC. Capecitabine (C) is approved in MBC pts pretreated with anthracycline and taxane. Methods: A standard 3+3 escalation scheme explored doses of combined intravenous

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9dfa5f61f88c7019fbacfdaedfd4d080
https://doi.org/10.1200/jco.2009.27.15_suppl.1053

Zobrazit plný text záznamu

Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer –A pooled analysis of 254 patients included in 2 randomised trials

Autor: Dominique Méry-Mignard, E. Magherini, Ph. Rougier, C. Louvet, A. de Gramont, Emmanuel Mitry, Christophe Tournigand, J.-Y. Douillard, T. Andre, David Cunningham

Publikováno v: Journal of Clinical Oncology. 22:3576-3576

3576 Background: With only one 5FU bolus injection and an increased dose of 5FU by continuous infusion, the simplified LV5FU2 regimen is considered as effective as but less toxic and more convenient than the original LV5FU2 de Gramont regimen [Tourni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1502503f78dcd31e8fda3b10d7dae944
https://doi.org/10.1200/jco.2004.22.90140.3576

Zobrazit plný text záznamu

5FU-leucovorin (5FU/LV) with or without irinotecan (CPT-11) in stages II-III rectal cancers: Preliminary safety analysis of the French Intergroup R98 phase III trial

Autor: E. Magherini, Ph. Rougier, Pascal Piedbois, Ayman Zawadi, M. Ychou, T. Andre, J.-Y. Douillard, Marc Buyse, Emmanuel Achille, T. Muron

Publikováno v: Journal of Clinical Oncology. 22:3549-3549

3549 Background:The optimal adjuvant treatment of stages II-III rectal cancers is still debatable. When administered, postoperative chemotherapy is usually a 5FU-leucovorin (5FU/LV) regimen. CPT-11...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d96aa5331fece0ea6a4eb4c7966a6b5f
https://doi.org/10.1200/jco.2004.22.90140.3549

Zobrazit plný text záznamu

Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC)

Autor: J.-Y. Douillard, M. Ducreux, C. Oprea, G. Pascal, Bernard Nordlinger, Jean-Luc Raoul, Michel Rivoire, René Adam, M.-C. Clavero-Fabri, E. Magherini

Publikováno v: Journal of Clinical Oncology. 22:3692-3692

3692 Background: Surgical resection of LM is the only treatment able to offer long term survival (30–35% at 5 years); however most LM are initially unresectable. Methods: The aim of this retrospect...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::08c5f841b0c422d56362050de6a7fe68
https://doi.org/10.1200/jco.2004.22.90140.3692

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání